Mersana Therapeutics (MRSN) Expected to Announce Earnings on Wednesday

Mersana Therapeutics (NASDAQ:MRSN) is anticipated to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $7.64 million for the quarter.

Mersana Therapeutics Price Performance

Shares of MRSN opened at $0.58 on Wednesday. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a twelve month low of $0.49 and a twelve month high of $6.28. The stock has a market capitalization of $71.99 million, a P/E ratio of -0.96 and a beta of 1.39. The company has a 50 day moving average of $1.08 and a 200-day moving average of $1.62.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. William Blair assumed coverage on shares of Mersana Therapeutics in a research report on Thursday, February 6th. They issued an “outperform” rating for the company. Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price (down previously from $7.00) on shares of Mersana Therapeutics in a research report on Friday, January 10th. Finally, Citigroup began coverage on Mersana Therapeutics in a report on Friday, November 15th. They set a “buy” rating and a $5.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Mersana Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $5.57.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.